Kymera Therapeutics, Inc. (KYMR)

Kymera Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	78.59	46.83	72.83	34.03	2.93
Revenue Growth (YoY)	67.84%	-35.71%	114.00%	1059.99%	-
Gross Profit	78.59	46.83	72.83	34.03	2.93
Selling, General & Admin	55.04	43.83	36.35	18.23	7.98
Research & Development	189.08	164.25	137.02	62.11	37.16
Operating Expenses	244.12	208.08	173.36	80.34	45.14
Operating Income	-165.53	-161.26	-100.53	-46.3	-42.21
Interest Expense / Income	0.2	0.18	0.18	0.12	0.05
Other Expense / Income	-18.76	-6.62	-0.49	-0.83	-1.01
Pretax Income	-146.96	-154.81	-100.22	-45.59	-41.25
Net Income	-146.96	-154.81	-100.22	-45.59	-41.25
Preferred Dividends	0	0	0	9.05	0
Net Income Common	-146.96	-154.81	-100.22	-54.64	-41.25
Shares Outstanding (Basic)	58	54	48	17	2
Shares Outstanding (Diluted)	58	54	48	17	2
Shares Change	8.22%	12.39%	176.60%	921.45%	-9.44%
EPS (Basic)	-2.52	-2.87	-2.09	-3.15	-24.28
EPS (Diluted)	-2.52	-2.87	-2.09	-3.15	-24.28
Free Cash Flow	-137.31	-155.92	-130.54	79.03	17.37
Free Cash Flow Per Share	-2.35	-2.89	-2.72	4.55	10.23
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-210.62%	-344.37%	-138.03%	-136.05%	-1438.48%
Profit Margin	-186.99%	-330.60%	-137.60%	-160.55%	-1405.79%
Free Cash Flow Margin	-174.71%	-332.98%	-179.24%	232.22%	592.13%
EBITDA	-143.2	-151.66	-97.65	-43.72	-40.38
EBITDA Margin	-182.21%	-323.87%	-134.07%	-128.45%	-1376.11%
Depreciation & Amortization	3.57	2.98	2.4	1.76	0.83
EBIT	-146.77	-154.63	-100.04	-45.48	-41.2
EBIT Margin	-186.74%	-330.23%	-137.36%	-133.63%	-1404.23%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).